We manage a global network of 101 subsidiaries (as of 2024.09.30).
(11 in Korea, 12 in the U.S., 27 in Australia, 50 in Singapore, and 1 in Japan)
- Korean Subsidiaries
-
- Founded in June 2018 as a specialized contract manufacturing organization (CMO) following the spinoff of CHA Biotech’s basic research division.
- With CHA Biotech's expertise in cell therapy manufacturing, Matica Biolabs focuses on immune cell therapy R&D and advancing the CDMO business in cell therapies, setting itself apart through its core capabilities
- Acquired in November 2012 to become a specialized bio and pharmaceutical company through the transfer of CHA Biotech’s pharmaceutical operations and discovery of new pipelines
- Specializes in the production and sale of pharmaceuticals, with a focus on the oral thin film (OTF) business
- Utilizing its proprietary Star Film Technology, CMG Pharmaceutical is developing OTF products such as Zypadhera and Aripiprazole
- A leading biotech firm dedicated to developing vaccines and immunotherapies
- Successfully demonstrated the efficacy of a third-generation hepatitis B vaccine in clinical trials, specifically for non-responders to traditional vaccines
- Also developing a therapeutic vaccine for chronic hepatitis B and recombinant protein drugs using its unique immune-boosting adjuvant technology
- A clinical research organization specializing in clinical trials for pharmaceuticals and medical devices, with deep expertise in the highly specialized field of stem cell therapy trials
- Offers comprehensive clinical trial management and regulatory services for domestic pharmaceutical and medical device companies, and project management for global clinical trials
- Established in August 2013 through the division of CHA Biotech’s bio-development business, specializing in the production of biomaterials and medical devices
- Successfully developed various medical products, including the hyaluronic acid-based filler “Hiafillia” and the water-based injection treatment “Belona,”now sold in beauty centers and aesthetic clinics both in Korea and internationally
- Provides integrated facility management services for hospitals, schools, and businesses, including specialized services for medical facilities
- Operates family care services such as elder care, maternity care, and funeral services, while also delivering comprehensive corporate health management programs focused on disease prevention and health promotion for employees
- Founded in August 2013 as Korea's only hospital management company
- Currently operating LA CHA Hollywood Presbyterian Medical Center (HPMC) in the U.S., CFC in Australia, and SMG in Singapore
- Leveraging its extensive hospital management expertise and brand value, CHA Healthcare is expanding its overseas operations through hospital acquisitions and partnerships with local medical institutions
- A venture capital firm established in June 2011, focusing on high-growth sectors such as biotechnology, agri-food, green energy, and IT
- Recognized for its ability to identify and invest in promising companies across diverse industries
- Solidus Investment co-manages a KRW 1.5 trillion global healthcare fund with KB Investment and Korea Venture Fund, further enhancing its competitiveness in the global market
- Major Overseas Subsidiaries
-
- Founded in 1924 and acquired from Tenet Health Systems in 2004
- The largest private general hospital in Los Angeles, boasting 434 beds
- Stands as the first Korean-owned general hospital to expand internationally
- Strong reputation in obstetrics and gynecology, performing over 4,000 deliveries annually, making it the top facility for childbirth in LA
- Currently undergoing a massive $400 million renovation and expansion project, the new patient tower will feature state-of-the-art facilities, including an emergency center, inpatient rooms, labor and delivery suites, a neonatal intensive care unit (NICU), and a cardiac catheterization lab
- Matica Biotechnology, based in Texas, is CHA Biotech’s U.S. subsidiary specializing in contract development and manufacturing (CDMO) for biopharmaceuticals
- Focused on developing and producing viral vectors - critical components in gene-edited cell therapies such as CAR-T (third-generation cancer therapies)
- Matica is at the forefront of CHA Biotech’s global CDMO expansion
- As a key hub, Matica recruits top industry talent, advances technological innovation, and identifies new business opportunities
- Collaborating with cell and gene therapy developers aiming for rapid clinical advancement, Matica is broadening its U.S. market presence
- In partnership with Texas A&M University’s CIADM program, Matica completed its first state-of-the-art CDMO facility for cell and gene therapies in College Station, Texas, in 2022
- Currently, the facility is being upgraded to expand capacity for commercial-scale production, and a second plant is under development
- Matica is accelerating its business growth through partnerships with U.S. developers seeking fast-tracked clinical trials
- ※ Contract Development and Manufacturing Organization (CDMO)
: End-to-end services, from drug development and production to large-scale commercialization
- Established in 2003, City Fertility Center is a top-tier IVF clinic network offering a range of specialized services, including egg freezing and genetic testing
- With a robust foundation in assisted reproductive technology, City Fertility operates 27 clinics and consulting rooms across Australia’s major cities, including Brisbane, Melbourne, Sydney, and Perth, serving both the east and west coasts
- Singapore Medical Group offers specialized medical care across several fields, including oncology, women’s health (obstetrics and gynecology), pediatrics, plastic surgery, and dermatology
- SMG operates 46 clinics across Singapore, Vietnam, and Indonesia, providing comprehensive and specialized healthcare services in these regions